About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
minkabu the infonoid
(C) 2024 MINKABU THE INFONOID, Inc.
kabutan

CanBas Co.,Ltd.(4575) Summary

4575
TSE Growth
CanBas Co.,Ltd.
921
JPY
+14
(+1.54%)
Apr 16, 11:30 am JST
6.45
USD
Apr 15, 10:30 pm EDT
Result
PTS
outside of trading hours
919.8
Apr 16, 11:29 am JST
Summary Chart Historical News Financial Result
PER
PBR
5.89
Yield
ー%
Margin Trading Ratio
Stock Price
Apr 16, 2025
Opening Apr 16, 9:00 am
911 JPY 6.36 USD
Previous Close Apr 15
907 JPY 6.34 USD
High Apr 16, 10:38 am
936 JPY 6.55 USD
Low Apr 16, 9:00 am
903 JPY 6.30 USD
Volume
125,000
Trading Value
0.12B JPY 0.81M USD
VWAP
920.37 JPY 6.45 USD
Minimum Trading Value
92,100 JPY 645 USD
Market Cap
0.02T JPY 0.12B USD
Number of Trades
332
Liquidity & Number of Trades
As of Apr 16, 2025
Liquidity
High
1-Year Average
1,746
1-Year High Sep 18, 2024
27,787
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 11, 2025 0 1,474,700
Apr 4, 2025 0 1,616,200
Mar 28, 2025 0 1,648,200
Mar 21, 2025 0 1,746,900
Mar 14, 2025 0 1,748,600
Company Profile
CanBas Co., Ltd. is a drug discovery venture specializing in anticancer drug development. Its primary source of income is research and development support funds. The company is actively seeking partnership opportunities.
Sector
Pharmaceuticals
CanBas Co., Ltd. is a drug discovery venture focusing on basic research, early clinical development, and late-stage clinical development of anticancer drugs. Leveraging its unique drug discovery approach, the company has a development pipeline consisting of multiple drug candidate compounds. CanBas utilizes external specialized institutions and a scientific advisory board, aiming for synergy by combining in-house development with strategic partnerships with pharmaceutical companies. The company's lead compound, CBP501, is currently undergoing Phase 2 clinical trials in combination with immune checkpoint inhibitor antibodies. CBS9106 has been licensed to a U.S. company and is progressing through clinical development. In addition to these, CanBas is conducting exploratory research on multiple novel candidate compounds. The company's immediate priorities are accelerating the development of CBP501 and maximizing its chances of success, while continuing basic research to deepen understanding of existing pipelines and generate next-generation pipelines. Continuous fundraising through direct financing is also positioned as one of the company's challenges and strategies to support these efforts.